FDA Brief

Warning letters Drugs

FDA warning letter to

Pharmedica USA, LLC

High riskIssued Apr 28, 2023Posted May 16, 2023Division of Pharmaceutical Quality Operations IV

FDA found Pharmedica made ophthalmic and nasal drugs under insanitary conditions without required sterile controls.

What happened

FDA inspected Pharmedica's Phoenix drug manufacturing facility from November 1 to November 7, 2022 and found insanitary conditions, including no ISO classified areas such as ISO 5 for sterile drug production and a facility in disrepair. FDA also cited CGMP violations: no adequate aseptic or sterility controls for an OTC ophthalmic product, no process validation, inadequate release and component testing, and an inadequate quality unit. The company later ceased drug manufacturing and recalled Purely Soothing 15% MSM Drops worldwide because they were not sterile.

What FDA found

  1. FDA found sterile-intended ophthalmic drug products made in a facility that lacked ISO classified areas and was in disrepair, creating a risk of contamination.

    section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)
  2. The firm lacked adequate written procedures and validation to prevent microbiological contamination and did not have adequate separate or defined aseptic processing areas.

    21 CFR 211.113(b) & 211.42(c)(10)
  3. The firm did not qualify equipment or validate manufacturing processes, including process performance qualification and ongoing process monitoring.

    21 CFR 211.100(a)
  4. The firm did not perform adequate release testing for each batch, including sterility testing for ophthalmic products and testing for objectionable microorganisms in nasal spray.

    21 CFR 211.165(a) and 21 CFR 211.165(b)
  5. The firm did not adequately test components and did not establish the reliability of supplier test results or obtain and review all supplier certificates of analysis.

    21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)
  6. The quality control unit failed to ensure adequate procedures, a stability program, complete batch records, and adequate deviation investigations.

    21 CFR 211.22, 211.166(a), 211.188, 211.192

What FDA wants

FDA tells Pharmedica to correct the violations promptly and respond in writing within 15 working days with the actions taken and plans to prevent recurrence. If the firm resumes drug manufacturing, it must notify FDA before resuming and provide a CAPA summary; FDA also recommends a qualified consultant and a six-system CGMP audit.

Who should pay attention

  • brands that contract with Pharmedica for ophthalmic or nasal drug products
  • companies buying or distributing Purely Soothing products
  • drug manufacturers outsourcing sterile ophthalmic production

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. ABC Food Corp

    ABC Food Corp's ready-to-eat rice noodles and tofu were made without required hazard analysis and preventive controls.

    High risk
  3. Rama Food Manufacture Corp.

    FDA warns Rama Food Manufacture after inspections found insanitary conditions and preventive-control failures at its California ready-to-eat rice noodle plants.

    High risk
  4. Lewis Sausage Company Inc.

    FDA found Salmonella and Listeria in contract-made pet food from Lewis Sausage and says its pathogen controls are inadequate.

    High risk